Genetic Testing (PGT/PGD) in Kolkata: Your Complete Guide to Safer IVF Outcomes

Preimplantation Genetic Testing (PGT) is an umbrella term covering several distinct embryo-screening techniques performed during an IVF cycle before uterine transfer. Preimplantation Genetic Diagnosis (PGD) — now clinically reclassified as PGT-M (for monogenic disorders) — screens embryos for specific inherited single-gene diseases or chromosomal structural rearrangements carried by one or both parents. Preimplantation Genetic Testing for Aneuploidies (PGT-A), formerly called PGS, screens all 23 pairs of chromosomes in an embryo to detect missing or extra chromosomes, a leading cause of implantation failure and early miscarriage.

A third variant, PGT-SR, is used when a parent carries a chromosomal structural rearrangement such as a balanced translocation. Each type requires a small biopsy of 4–8 trophectoderm cells from the outer layer of the blastocyst — a procedure that does not harm the viable inner cell mass that becomes the baby. The biopsied cells are then sent to a specialist genetics laboratory for next-generation sequencing (NGS) or array CGH analysis.

For Kolkata couples, the HomeIVF Medical Board recommends understanding which specific PGT variant applies to your clinical situation before proceeding, as candidacy criteria, laboratory requirements, and cycle protocols differ meaningfully between PGT-A, PGT-M, and PGT-SR.

Not every IVF patient requires genetic testing, but for specific clinical profiles, PGT can be the single most impactful addition to a treatment cycle. The HomeIVF Medical Board identifies the following groups as primary candidates in a Kolkata clinical context.

Couples with recurrent implantation failure — defined as two or more failed transfers of good-quality embryos — often harbour chromosomally abnormal embryos that appear morphologically normal under standard microscopy. PGT-A identifies which embryos are euploid (chromosomally balanced) and therefore most likely to implant.

Women of advanced maternal age (typically 35 and above) produce a higher proportion of aneuploid eggs. For a 40-year-old patient, studies suggest that up to 70–80% of blastocysts may be chromosomally abnormal, making PGT-A particularly valuable.

In West Bengal, the carrier frequency for beta-thalassaemia is notably elevated. Couples in communities across Kolkata — including many families in Ballygunge, North Kolkata, and the broader Bengali diaspora — who have already lost a child to thalassaemia major or who are both identified carriers have the strongest indication for PGT-M. Similarly, couples with a family history of Duchenne muscular dystrophy, spinal muscular atrophy, or fragile X syndrome are strong PGT-M candidates.

Couples with recurrent pregnancy loss (three or more consecutive miscarriages) and those where one partner carries a chromosomal translocation round out the core candidate list.

A successful PGT cycle begins weeks or even months before egg retrieval. The diagnostic pathway is more structured than a standard IVF cycle and requires careful co-ordination between the fertility clinic, the genetics laboratory, and the patient.

Step one is carrier screening and karyotyping. Both partners undergo blood-based chromosomal analysis and, where PGT-M is indicated, targeted gene sequencing to confirm carrier or affected status. For thalassaemia PGT-M in Kolkata, this may include HPLC, gap-PCR, and ARMS testing to precisely characterise the mutation type — critical because the probe designed for the embryo biopsy must match the exact mutation.

Step two is probe or assay design. For PGT-M, the genetics laboratory designs a customised mutation-specific probe — a process that typically takes 4–8 weeks in India. HomeIVF coordinates directly with accredited NGS laboratories to ensure Kolkata patients are not delayed by administrative gaps between the clinic and lab.

Step three is the stimulated IVF cycle, egg retrieval, fertilisation via ICSI, and blastocyst culture to Day 5 or 6. The trophectoderm biopsy is then performed by a senior embryologist, cells are vitrified or immediately dispatched to the genetics lab, and the embryo itself is frozen to await results. The final step is a frozen embryo transfer (FET) of the selected euploid or unaffected embryo in a subsequent cycle.

West Bengal carries one of the highest burdens of beta-thalassaemia in India. The Indian Council of Medical Research estimates that approximatelystarting from ₹1.5 lakhthalassaemia-affected children are born in India each year, and West Bengal accounts for a disproportionate share. For families in Kolkata who have already experienced the profound grief of raising a child with thalassaemia major — or who have terminated an affected pregnancy — PGT-M offers a proactive, ethically sound alternative to prenatal diagnosis.

When both parents are confirmed beta-thalassaemia carriers, each natural pregnancy carries a 25% chance of producing an affected child. PGT-M allows embryos to be genetically assessed before transfer, selecting only unaffected or carrier embryos for implantation. This effectively eliminates the clinical need for chorionic villus sampling (CVS) or amniocentesis in that cycle, sparing the couple the anxiety of mid-trimester termination decisions.

HomeIVF's care coordinators in Kolkata work closely with haematology teams and NABL-accredited molecular genetics laboratories to ensure the mutation characterisation and probe design phases proceed without avoidable delays — a common pain point for families who have navigated this journey alone in the past. Patients from communities in and around New Town and the Salt Lake Sector V technology corridor have used HomeIVF's telemedicine platform to begin this diagnostic process from home, reducing unnecessary clinic visits during emotionally demanding periods.

A complete PGT cycle in Kolkata involves more steps than a standard IVF cycle, and realistic timeline expectations are essential to reduce patient anxiety and improve compliance.

For PGT-A patients, the additional time beyond a standard IVF cycle is primarily the 10–21 working days required for NGS results after embryo biopsy. Because the embryo is vitrified post-biopsy and transferred in a subsequent frozen cycle, the total timeline from stimulation start to embryo transfer is typically 6–10 weeks.

For PGT-M patients (e.g., thalassaemia), the probe design phase extends the pre-cycle preparation to 8–16 weeks from the point of confirmed carrier status. The stimulated cycle and biopsy procedure itself is structurally identical to PGT-A. Couples should plan for a 4–6 month total commitment from initial consultation to embryo transfer.

HomeIVF IVF packages starting from ₹1.5 lakh include co-ordination across this extended timeline, with dedicated care coordinators who track each phase — from genetics lab dispatch confirmations to FET scheduling. Patients based in Behala or other peripheral Kolkata localities benefit particularly from HomeIVF's home-monitoring service, which reduces the number of clinic visits required for blood draws, ultrasound monitoring, and medication counselling during the stimulation phase.

One of the most underappreciated stressors in a PGT cycle is the sheer volume of monitoring appointments required — baseline scans, stimulation ultrasounds, hormone assays, and post-retrieval checks. For a couple already managing the emotional weight of genetic testing decisions, commuting across Kolkata to a fertility clinic for every monitoring visit can be physically and psychologically exhausting.

HomeIVF addresses this directly by deploying trained fertility nurses and portable diagnostic equipment to patients' homes across Kolkata. This service covers follicle tracking ultrasounds, serum estradiol and progesterone blood draws, and medication administration support. The results feed in real time to the HomeIVF Medical Board's reviewing specialists, who adjust stimulation protocols remotely and communicate with the treating IVF clinician.

This model is particularly impactful for patients in areas with dense traffic and limited specialist clinic presence — such as Behala in south-west Kolkata, or the outer peripheries of the Salt Lake township. By eliminating 40–60% of in-clinic monitoring visits, HomeIVF reduces both logistical burden and the cumulative stress response that can negatively affect IVF outcomes. Senior-specialist oversight is maintained at every stage; HomeIVF does not replace specialists, it delivers that specialist-grade care closer to where Kolkata patients live.

A common question from Kolkata patients is: does PGT actually improve my chances of taking home a baby? The honest answer is nuanced and depends on the specific PGT type, the patient's age, and the underlying indication.

For PGT-A, the strongest evidence supports its use in women of advanced maternal age and in patients with recurrent implantation failure. Transferring a single euploid blastocyst in a well-prepared FET cycle achieves clinical pregnancy rates of 50–65% per transfer in many published series — significantly higher than transferring morphology-selected embryos without chromosomal screening. However, for younger women (under 35) with good ovarian reserve and no prior failures, the incremental benefit of PGT-A is more modest, because a higher proportion of their embryos are already euploid.

For PGT-M in conditions like thalassaemia, the success metric shifts: the primary goal is an unaffected pregnancy, not simply a positive pregnancy test. Live birth rates per transfer from unaffected embryos are broadly comparable to standard IVF success rates — typically 40–55% per cycle in India depending on age and additional factors — but with the added certainty that the transferred embryo does not carry two disease-causing alleles.

The HomeIVF Medical Board emphasises that no genetic test guarantees a live birth. PGT does not screen for all chromosomal or genetic abnormalities, and a small residual risk of diagnostic error (typically under 2%) remains. Transparent pre-treatment counselling on these limitations is a non-negotiable part of the HomeIVF process for every Kolkata patient.

Despite the clear clinical value of PGT, several structural barriers have historically limited access for Kolkata patients. The HomeIVF Medical Board has identified three primary friction points and how HomeIVF's model directly addresses each.

First, fragmentation between fertility clinics and genetics laboratories. Many IVF clinics in Kolkata send biopsy samples to external labs without a dedicated coordination mechanism, leading to delays, sample tracking failures, and result miscommunications. HomeIVF maintains formal service agreements with NABL-accredited molecular genetics laboratories experienced in reproductive genetics, ensuring a defined chain of custody and turnaround commitment.

Second, lack of pre-test genetic counselling. PGT — especially PGT-M for serious conditions like thalassaemia — requires robust informed consent and counselling on the ethical, emotional, and clinical dimensions. Many patients from Ballygunge, New Town, and other Kolkata localities report having proceeded to testing without fully understanding the probe design phase or the possibility that all embryos in a cycle may be affected. HomeIVF embeds genetic counselling sessions into every PGT pathway at no additional coordination cost.

Third, financial opacity. The cost of PGT in India varies widely and is rarely itemised clearly. HomeIVF provides a transparent, itemised cost breakdown covering stimulation monitoring, biopsy, genetics lab fees, vitrification, and FET — so Kolkata families can plan financially without encountering unexpected add-ons at each stage of the process.